Soligenix, Inc. (SNGX) — SEC Filings
Soligenix, Inc. (SNGX) — 40 SEC filings. Latest: 424B3 (May 8, 2026). Includes 17 8-K, 6 10-Q, 4 EFFECT.
View Soligenix, Inc. on SEC EDGAR
Overview
Soligenix, Inc. (SNGX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 3, 2026: Soligenix, Inc. filed an EFFECT form with the SEC on April 3, 2026, indicating the effectiveness of a registration statement. The effectiveness date is April 2, 2026, related to Act 33 and File No. 333-290413.
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Soligenix, Inc. is neutral.
Filing Type Overview
Soligenix, Inc. (SNGX) has filed 1 424B3, 4 EFFECT, 17 8-K, 6 10-Q, 3 S-1, 2 DEF 14A, 2 10-K, 4 DEFA14A, 1 S-1/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of SNGX's 36 recent filings, 6 were flagged as high-risk, 18 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$8,184,191 |
| EPS | -$0.58 |
| Debt-to-Equity | 0.49 |
| Cash Position | $10,525,335 |
| Operating Margin | N/A |
| Total Assets | $11,293,917 |
| Total Debt | $3,695,941 |
Key Executives
- Christopher J. Schaber, Ph.D.
- Driscoll R. Ugarte, Esq.
Industry Context
Soligenix operates in the highly competitive biotechnology and pharmaceutical sector, focusing on developing treatments for rare and orphan diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include advancements in targeted therapies and the increasing demand for treatments for unmet medical needs.
Top Tags
corporate-governance (7) · sec-filing (6) · filing (6) · financials (6) · registration-statement (4) · financial-reporting (4) · 8-K (4) · 10-Q (4) · material-agreement (4) · Soligenix (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-02 | The date the SEC declared the registration statement effective. |
| Filing Date | 2026-04-03 | The date the filing was accepted by the SEC. |
| File Number | 333-271049 | The SEC file number associated with this registration. |
| Commission File Number | 001-14778 | Identifies the specific SEC filing |
| EIN | 41-1505029 | Employer Identification Number for Soligenix, Inc. |
| Net Loss | $8,184,191 | for the nine months ended September 30, 2025, increased from $5,279,210 in 2024 |
| Research and Development Expenses | $5,202,573 | for the nine months ended September 30, 2025, up from $2,564,887 in 2024 |
| Cash and Cash Equivalents | $10,525,335 | as of September 30, 2025, up from $7,819,514 at December 31, 2024 |
| Proceeds from September 2025 Public Offering | $7,498,522 | contributed to financing activities |
| Accumulated Deficit | $242,154,943 | as of September 30, 2025 |
| Cash Used in Operating Activities | $7,521,449 | for the nine months ended September 30, 2025 |
| Common Shares Outstanding | 9,861,130 | as of September 30, 2025, increased from 2,514,499 at December 31, 2024 |
| Basic and Diluted Net Loss Per Share | $0.58 | for the three months ended September 30, 2025, improved from $0.78 in 2024 |
| Maximum gross proceeds from offering | $8.0 million | Targeted capital raise to address Nasdaq compliance and fund operations |
| Stockholders' equity as of June 30, 2025 | $1,828,951 | Below Nasdaq's minimum requirement, triggering the non-compliance notice |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Soligenix, Inc. (SNGX)?
Soligenix, Inc. has 40 recent SEC filings from Jan 2024 to May 2026, including 17 8-K, 6 10-Q, 4 EFFECT. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SNGX filings?
Across 40 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 33 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Soligenix, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Soligenix, Inc. (SNGX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Soligenix, Inc.?
Key financial highlights from Soligenix, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SNGX?
The investment thesis for SNGX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Soligenix, Inc.?
Key executives identified across Soligenix, Inc.'s filings include Christopher J. Schaber, Ph.D., Driscoll R. Ugarte, Esq..
What are the main risk factors for Soligenix, Inc. stock?
Of SNGX's 36 assessed filings, 6 were flagged high-risk, 18 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Soligenix, Inc.?
Forward guidance and predictions for Soligenix, Inc. are extracted from SEC filings as they are enriched.